Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. - Gibb A; Jones C; Bloor A; Kulkarni S; Illidge T; Linton K; Radford J (Haematologica, 2013)